Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-143342

Published: 2020

Journal Articles

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Karen Sweiss, PharmD, Eric Wenzler, Hung H Nguyen, MLS, Avadhut D Joshi, PhD, Rosa Yeh, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Donald Irby, PhD, Mitch A. Phelps, PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143430

Published: 2020

Journal Articles

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Karen Sweiss, PharmD, Benjamin G Barwick, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Craig C Hofmeister, MDMPH, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-143422

Published: 2020

Journal Articles

A Study Highlighting the Limited Use of Autologous Hematopoietic Stem Cell Transplant for Fit Elderly Patients with Multiple Myeloma in India

Swaroop Revannasiddaiah, MD, Prathap Raja Varma, Pharm D, Apoorva Jagadish, MBBS, Rasmi Palassery, MD, Vinayak V Maka, MD DM, Nalini Kilara, MDDM, Deepa Dhanabalan, MD, Kalpana Kumari, MD, Damiano Rondelli, MD, Santhosh Kumar Devadas, MD DM

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137651

Published: 2020

Journal Articles

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139575

Published: 2020

Journal Articles

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Jaime Holden, BFA, Paulina Lewkowski, BS, Iryna Mialik, AS, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 1980.

https://doi.org/10.1182/blood-2019-131886

Published: 2019

Journal Articles

Monitoring of Stored Hematopoietic Stem/Progenitor Graft Stability Program in a Single Institute

Youngmin Park, MS, Grace Irene, BS, Amudha Ganapathy, PhD, Dolores Mahmud, PhD, Pritesh Patel, MB, ChB, Damiano Rondelli, MD, Nadim Mahmud, MBBS, PhD

Blood (2019) 134 (Supplement_1): 1968.

https://doi.org/10.1182/blood-2019-132145

Published: 2019

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3081.

https://doi.org/10.1182/blood-2019-131914

Published: 2019

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Bhaskar Vemu, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, John G. Quigley, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Jeremy Johnson, PharmD, PhD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3310.

https://doi.org/10.1182/blood-2019-132216

Published: 2019

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Blood (2018) 132 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2018-99-111929

Published: 2018

Journal Articles

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

Santosh L. Saraf, MD, Krishna Ghimire, MD, Pritesh Patel, MD, Karen Sweiss, PharmD, John G. Quigley, Irum Khan, MBBS, David Peace, MD, Michel Gowhari, DO, Shivi Jain, MD, John P. Galvin, MDMS,MPH, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 313.

https://doi.org/10.1182/blood-2018-99-113666

Published: 2018

Journal Articles

A New Prognostic Score Using Lymphocyte to Monocyte Ratio and Immunoglobulin Levels to Predict Progression in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Jonathan Lee, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2018-99-118965

Published: 2018

Journal Articles

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Sonia Christian, MD, Kelley E. Kozma, DO, Stephanie Barath, Ardaman Shergill, MD, Damiano Rondelli, MD, David Peace, MD, Santosh L. Saraf, MD, Annie Lee Oh, MD, Karen Sweiss, PharmD, Irum Khan, MBBS, Pritesh Patel, MD, Arkadiusz Dudek, MD PhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 5218.

https://doi.org/10.1182/blood-2018-99-111412

Published: 2018

Journal Articles

Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Jeremy Johnson, PharmD, PhD, Hyunyoung Jeong, PharmD, PhD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2018-99-117623

Published: 2018

Journal Articles

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Blood (2018) 132 (Supplement 1): 577.

https://doi.org/10.1182/blood-2018-99-111946

Published: 2018

Journal Articles

Survival Analysis in Patients of AML with Myelodysplasia Related Changes

Krishna Ghimire, MD, Mahesh Nepal, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 5906.

https://doi.org/10.1182/blood-2018-99-120236

Published: 2018

Journal Articles

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Scott Wirth, PharmD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2018-99-117657

Published: 2018

Journal Articles

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Pritesh Patel, MD, Vitalyi Senyuk, PhD, Natalie S. Rodriguez, MS, Dolores Mahmud, PhD, Annie Lee Oh, MD, Nadim Mahmud, MBBS, PhD, Giovanni Barosi, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2018-99-119497

Published: 2018

Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 321.

https://doi.org/10.1182/blood.V130.Suppl_1.321.321

Published: 2017

NARROW

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

A Study Highlighting the Limited Use of Autologous Hematopoietic Stem Cell Transplant for Fit Elderly Patients with Multiple Myeloma in India

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

Monitoring of Stored Hematopoietic Stem/Progenitor Graft Stability Program in a Single Institute

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

A New Prognostic Score Using Lymphocyte to Monocyte Ratio and Immunoglobulin Levels to Predict Progression in Multiple Myeloma Patients Undergoing Autologous Transplant

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Survival Analysis in Patients of AML with Myelodysplasia Related Changes

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only